XML 25 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Millions
Total
Common Stock
[1]
Treasury Stock
[1]
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Equity Attributable to Noncontrolling Interests
Share Repurchase Program
Treasury shares 22,300,000              
Common stock, shares outstanding 501,900,000              
Beginning balance at Dec. 31, 2018 $ 2,185 $ 5 $ (1,487) $ 1,026 $ 3,270 $ (629) $ 0  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 1,500       1,500   0  
Other comprehensive loss $ (97)         (97) 0  
Stock-based compensation 0              
Treasury Stock, Shares, Acquired 1,800,000             5,800,000
Share-based compensation awards [2] $ 73   71 15 (13)      
Share repurchase program 0              
Treasury stock acquired [3] $ (626)   (626)          
Employee benefit plan contribution from Pfizer Inc. [4] 3     3        
Dividends declared (330)       (330)      
Ending balance at Dec. 31, 2019 $ 2,708 5 (2,042) 1,044 4,427 (726)    
Treasury shares 26,400,000              
Common stock, shares outstanding 501,900,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income $ 1,636       1,638   (2)  
Other comprehensive loss $ (4)         (4) 0  
Stock-based compensation 0              
Treasury Stock, Shares, Acquired 1,600,000             1,800,000
Share-based compensation awards [2] $ 78   62 18 (2)      
Share repurchase program 0              
Treasury stock acquired [3] $ (250)   (250)          
Employee benefit plan contribution from Pfizer Inc. [4] 3     3        
Dividends declared (404)       (404)      
Ending balance at Dec. 31, 2020 $ 3,773 5 (2,230) 1,065 5,659 (730) 4  
Treasury shares 26,573,492              
Common stock, shares outstanding 501,891,243              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income $ 2,034           (3)  
Other comprehensive loss $ (34)         (34) 0  
Treasury Stock, Shares, Acquired 1,300,000             4,000,000.0
Share-based compensation awards [2] $ 20   21   (1)      
Treasury stock acquired [3] (743)   (743)          
Employee benefit plan contribution from Pfizer Inc. [4] 3     3        
Dividends declared (509)       (509)      
Ending balance at Dec. 31, 2021 $ 4,544 $ 5 $ (2,952) $ 1,068 $ 7,186 $ (764) $ 1  
Treasury shares 29,317,153              
Common stock, shares outstanding 501,891,243              
[1] $4,550 
[2] Includes the issuance of shares of Zoetis Inc. common stock and the reacquisition of shares of treasury stock associated with exercises of employee share-based awards. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 15. Share-based Payments and Note 16. Stockholders' Equity.
[3] Reflects the acquisition of treasury shares in connection with the share repurchase program. For additional information, see Note 16. Stockholders' Equity.
[4] Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans. See Note 14. Benefit Plans.